Current clinical perspectives on myocardial angiogenesis by Mukherjee, Debabrata
Molecular and Cellular Biochemistry 264: 157–167, 2004.
c© 2004 Kluwer Academic Publishers. Printed in the Netherlands.
Review
Current clinical perspectives on myocardial
angiogenesis
Debabrata Mukherjee
Division of Cardiology, The University of Michigan, Ann Arbor, MI, USA
Abstract
Currently accepted modalities of treatment for atherosclerotic coronary artery disease (CAD) include pharmacological therapy,
and revascularization with either bypass surgery or percutaneous coronary intervention (PCI). Similarly, conventional treatment
of congestive heart failure (HF) is limited to medical therapy, temporary assist devices and in a select few, cardiac transplantation.
A significant subset of patients with severe symptomatic CAD and end stage HF is not eligible for these traditional methods of
treatment. In spite of maximal medical and revascularization therapy, these patients may not get adequate symptomatic relief.
After a decade of investigations, gene therapy is emerging as a promising therapeutic option for this group of patients. This
review discusses myocardial angiogenesis as a therapeutic modality in these patients including therapeutic angiogenesis with
growth factors and cell transplantation. (Mol Cell Biochem 264: 157–167, 2004)
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Introduction
There is a growing population of patients with coronary artery
disease (CAD) and heart failure (HF) who have refractory
symptoms despite maximal medical therapy. A significant
proportion of these patients may not be candidates for revas-
cularization with either percutaneous coronary intervention
(PCI) or coronary artery bypass surgery (CABG) [1]. These
include symptomatic patients with severe diffuse disease in
native coronary vessels and not candidates for PCI or CABG;
and patients with recurrent narrowing and occlusion of by-
pass conduits after successful surgery with no further revas-
cularization options. Although gene therapy for HF is still be-
ing tested, patients who continue to be limited by severe HF
symptoms despite aggressive medical management and who
are not eligible for assist devices or cardiac transplantation
may potentially benefit from these newer modalities of treat-
ment. We have previously demonstrated that approximately
5% of patients undergoing coronary angiography for angina
may not be candidates for traditional methods of revascular-
ization and may be eligible for newer modalities of therapy
[1]. Based on 1.4 million cardiac catheterizations performed
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in the US annually [2] around 70,000 patients per year may be
eligible for newer methods of treatment. Moreover, the prog-
nosis of these “no option” patients with refractory angina who
are not amenable to traditional modes of revascularization re-
mains poor with a mortality rate up to 17% at 1 year [3].
Maximal pharmacological therapy
The importance of optimum medical therapy in these patients
with symptomatic CAD who are not candidates for revas-
cularization cannot be overemphasized. Management in-
cludes discontinuation of tobacco use (all forms), lipid re-
duction with a target low-density lipoprotein <100 mg/dl,
and control of hyperglycemia. All patients with symptomatic
CAD should receive aspirin, beta-blockers, and angiotensin-
converting enzyme inhibitors, nitrates and lipid-lowering
agents. And, similarly patients with CHF (depending on the
underlying etiology) should receive maximal medical ther-
apy which includes the above-mentioned medications and in
addition spironolactone, digoxin and diuretics. Adherence
to salt restriction and modification of dietary habits also
play a very important role. Angiotensin-converting enzyme
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Table 1. Inclusion and exclusion criteria for candidacy for therapeutic
angiogenesis clinical trials
Inclusion criteria
Stable Canadian Cardiovascular Class III–IV angina
Refractory to maximum medical therapy
Area of ischemic myocardium on an imaging stress study
Severe coronary artery disease not amenable to CABG or PCI.
Exclusion criteria
Cancer
Fundoscopic signs of diabetic retinopathy
Severe left ventricular systolic dysfunction with an ejection fraction
of less than 20%
Unstable angina
Concurrent severe illness with markedly reduced life-expectancy
inhibitors not only have a salutary effect on left ventricular
function but are also anti-ischemic, and may have angiogenic
properties [4].
Eligibility for newer modalities
The inclusion and exclusion criteria for patients enrolled in
contemporary clinical trials for therapeutic angiogenesis are
listed in Table 1 [5]. For most of these trials, patients were
considered eligible if they had stable Canadian Cardiovascu-
lar Class (CCC) III–IV angina refractory to maximum medi-
cal therapy, ischemic myocardium on an imaging stress study,
and severe CAD that was not amenable to revascularization
with CABG or PCI. Patients have been excluded in most clin-
ical studies if they had evidence of cancer, fundoscopic signs
of diabetic retinopathy and severe left ventricular systolic
dysfunction with an ejection fraction of less than 20%.
Angiogenesis with growth factors
“Therapeutic angiogenesis” with growth factors involves in-
jection of growth factors capable of generating new blood
vessels in an ischemic milieu. This was initially investigated
successfully in patients with peripheral vascular occlusive
disease. The native biologic response to vascular occlusion
is development of collaterals and up-regulation of naturally
occurring angiogens. Currently, therapeutic angiogenesis is
being investigated in several arenas including myocardial is-
chemia, restenosis, HF and graft failure [6, 7] with a variety
of delivery options (Fig. 1) [8].
A number of gene therapy vectors have been developed,
including viral (retro- and adenoviruses) and non-viral vec-
tors (plasmid DNA). Gene transfer with naked plasmid DNA
is less efficient and viral vectors significantly increase gene
transfer efficiency [9]. Retroviruses integrate with the host
genome in a stable fashion, whereas adenoviruses lead to a
transient transgene expression [7]. Most of the cardiovascular
trials to date have used non-viral vectors [8]. Various method-
ology for gene delivery have been tried including intravascu-
lar, intramyocardial via thoracotomy or percutaneous catheter
technique and local delivery using microspheres coated with
recombinant growth factors [9]. A promising new technique
uses ultrasound with ultrasonic contrast agent and has been
shown to improve gene transfer efficiency by 15–20-fold [10–
12]. This may allow intravenous injection of growth factors
and obviate more invasive delivery methods in the future.
Angiogenesis for myocardial ischemia
Vascular endothelial growth factor (VEGF)
VEGF plays a pivotal role in the biology of angiogenesis and
consists of several members including VEGFs A, B, C, D, E.
The isoforms of VEGF-A have been used in most of the clin-
ical trials (VEGF-121 and -165) [7]. Numerous studies have
demonstrated that VEGF is up-regulated in the presence of
myocardial ischemia and its expression is mediated through a
factor called hypoxia inducible factor-1 (HIF-1). Both VEGF
plamid cDNA and protein have been used in clinical trials.
Intramyocardial injection of plasmid DNA encoding 165-
amino acid isoform of VEGF (phVEGF) was studied in 30
patients in a Phase I clinical trial [13]. Out of the 30 patients,
29 of them experienced reduced angina, and use of sublingual
nitroglycerin. Exercise tolerance improved after gene trans-
fer with complete elimination of angina in 12/20 patients at 6
months and in 7/10 patients followed over 12 months. Over-
all, at 1 year, CCC functional angina class had improved by at
least 2 classes in 27/30 patients and 14/30 patients were free
of angina with normal activities [13]. A following trial in 30
patients with chronic stable angina evaluated direct intramy-
ocardial injection of cDNA encoding for VEGF-2 via mini-
thoracotomy and these patients had similar clinical improve-
ment at 1-year [14]. Overall, at 1 year in these two, Phase I
clinical trials, there were two deaths, three acute myocardial
infarctions, one transient ischemic attack, and three episodes
of HF. None of these adverse events could be attributed to
gene transfer. They were likely related to underlying exten-
sive CAD and operative procedure in these high-risk popula-
tion [9]. Isner et al., demonstrated similar clinical magnitude
of clinical improvement at 1 year in 30 patients with class III
or IV angina using transepicardial VEGF-2 gene transfer [8].
A total of 13 consecutive patients with chronic stable angina
who failed conventional therapy were treated with intramy-
ocardial injection of phVEGF-165 via mini-thoracotomy
in a study by Vale et al. [15]. Objective evidence of im-
proved myocardial perfusion was documented both by dipyri-
damole SPECT-sestamibi perfusion scans and left ventricular
electromechanical mapping (EMM). These modalities were
used to distinguish ischemic from infarcted myocardium
and demonstrated significant improvement in myocardial is-
chemia after phVEGF gene transfer (15.26 ± 0.98% vs. 9.94
± 1.53%, p-value 0.004). These results indicated that gene
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Fig. 1. Delivery options for myocardial gene transfer. (a) Epicardial. After intraoperative intramyocardial injection, the transgene is distributed to local
cardiomyocytes and/or myocardial interstitium. (b) Endocardial. After catheter-based intramyocardial injection, the transgene is distributed in a similar way
to that described in (a). (c) Intracoronary. Catheter injection directly into coronary arteries delivers the transgene by means of the coronary arterial circulation
to a broad sample of cardiomyocytes and/or myocardial interstitium in the area subserved by the injected, source artery. (d) Retroperfusion. Cannulation
of a coronary sinus (or subselective vein) with concurrent occlusion of outflow from the coronary sinus distributes the transgene retrograde from coronary
venous circulation through the capillary bed to cardiomyocytes and interstitium in potentially all regions of left ventricular myocardium. (e) Intrapericardial.
Transthoracic access to pericardium using a specialized catheter permits delivery into the pericardial space with secondary distribution directly to epicardial
cardiomyocytes, and indirectly through the circulation shared by the peri- and epicardium. Reproduced from Isner [8].
transfer might successfully rescue hibernating myocardium
[15]. In a study by Henry et al., 15 patients with ischemic my-
ocardium who were not suitable for traditional revasculariza-
tion received intracoronary VEGF during coronary angiogra-
phy. There was improved myocardial perfusion, angiographic
evidence of increased collateral density and symptomatic im-
provement [16]. Losordo et al., demonstrated that five pa-
tients who were given intramyocardial injection of VEGF
DNA during minimally invasive surgery showed improve-
ment in angina, nuclear perfusion scans, and angiography
[17]. In another study using VEGF DNA, 16 patients with
severe angina underwent direct intramyocardial injection of
VEGF DNA. There was a significant decrease in anginal
episodes, decreased use of nitroglycerin, and a significant
improvement in perfusion [18]. A randomized trial of ther-
apeutic angiogenesis with one intracoronary and three intra-
venous injections of VEGF, the vascular endothelial growth
factor in ischemia for vascular angiogenesis (VIVA) demon-
strated that VEGF offered no improvement beyond placebo
in all measurements by day 60 [19]. By day 120, high-dose
VEGF resulted in significant improvement in angina and fa-
vorable trends in exercise time and angina frequency [19].
The negative results of this study can be possibly attributed
to intravenous as opposed to intracoronary or intramyocar-
dial administration of the growth factor and insufficient local
delivery of VEGF after intravenous injections.
Several other clinical studies have evaluated viral vectors
for gene transfer. Rosengart et al. performed a Phase I clin-
ical trial using intramyocardial injection of adenovirus vec-
tor expressing human VEGF. Gene transfer in conjunction
with CABG was compared to sole gene transfer via a mini-
thoracotomy was studied in 21 patients. Both the groups had
improvement in clinical angina and ischemic area. Myocar-
dial administration of AdVEGF was well tolerated and had
significant benefits at 30-day period [20]. At 6 months, similar
results were demonstrated indicating the need for Phase II
clinical trials [21]. The same investigators injected 10 patients
with adenoviral VEGF transepicardially using video-assisted
thoracotomy or thoracoscopy with symptomatic improve-
ment and one late death. Table 2 summarizes the major studies
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Table 2. Clinical studies of therapeutic angiogenesis
Author Angiogen Type of study N Delivery method End points Comments
Symes et al. [13] VEGF165 Observational/ 30 IM Ex. Tol angina Improved
Phase I
Fortuin et al. [14] VEGF-2 Observational 30 IM via MT Ex. Tol angina Improved
Isner et al. [8] VEGF-2 Observational 30 IM Class III/IV angina Improved
Lathi et al. [72] VEGF165 Observational 30 IM via MT Class III/IV angina Improved
Vale et al. [15] phVEGF165 Observational 13 IM via MT Perfusion Improved
Henry et al. [16] VEGF DNA Observational 15 IC Perfusion collaterals angina Improved
Losordo et al. [17] VEGF DNA Observational 5 IM Angina perfusion angiogram Improved
Losordo et al. [18] VEGF DNA Observational 16 IM Angina NTG use perfusion Improved reduced NTG use
Henry et al. [19] VEGF protein Randomized 178 IC vs. IV Angina Perfusion No improvement at 60 days
Rosengart et al. [21] Adenovirus Randomized 21 IM + CABG vs. IM Angina Ischemia Improved
VEGF via MT
Rosengart et al. [20] Adenovirus Observational 10 Trans-epicardial Angina Improved
VEGF
Grines et al. [30] FGF-4 DB/Randomized 79 IC vs. placebo Ex. Tol Improved
Laham et al. [25] FGF-2 Observational 24 Capsules implantation/ Perfusion Improved at high dose
CABG
Sellke et al. [26] FGF-2 Observational 8 IM beads/CABG Perfusion Three out of eight patients
improved
Udelson et al. [27] FGF-2 Observational 59 IC Perfusion Improved
Schumacher et al. [28] FGF-1 Randomized 20 IM/CABG vs. Placebo Collaterals Improved
Simons et al. [29] FGF-2 Randomized 337 IC Ex. Tol perfusion Improvement at 90 days but
not at 180 days
Ex. Tol: exercise tolerance; IM: intramuscular; IV: intravenous; IC: intracoronary; MT: mini-thoracotomy; CABG: coronary artery bypass graft; NTG:
nitroglycerin; DB: double blind; N = number of patients.
evaluating growth factors for therapeutic angiogenesis and
Fig. 2 demonstrates new blood vessel formation after in-
tramyocardial injection of phVEGF165.
Fibroblast growth factor (FGF)
FGFs have also been studied in various trials with promis-
ing results. Acidic FGF (FGF-1) and basic FGF (FGF-2) af-
fect various types of cells in addition to endothelial cells
like fibroblasts and smooth muscle cells. FGFs (FGF-1–9)
can also induce angiogenesis in vivo. FGF-1, FGF-2 and
FGF-5 have been the agents used most commonly [22–24].
FGF-2 was implanted via heparin alginate capsules near oc-
cluded vessels at the time of CABG by Laham et al. [25] and
improved perfusion was noted in patients receiving FGF-
2 in a dose-dependent manner. Eight patients undergoing
CABG received intramyocardial injections of FGF-2 in slow
release beads in an area of the myocardium not amenable
to revascularization in another study [26]. Three patients
demonstrated improved perfusion in the non-revascularized
region on follow-up nuclear perfusion scans [26]. Intracoro-
nary FGF-2 in patients who are not candidates for CABG has
shown improvement in reversible ischemia on SPECT my-
ocardial scan [27]. In a study by Schumacher et al. [28], 20
patients undergoing CABG received an intramyocardial in-
jection of FGF-1 near the insertion of the internal mammary
graft. Compared with 20 patients treated with placebo injec-
tions, the treated patients had evidence of increased collateral
growth at follow-up angiography (Fig. 3) [28]. The random-
ized FGF Initiating RevaScularizationTrial (FIRST) demon-
strated that a single intracoronary FGF-2 infusion seems to
resultin short-term symptomatic improvement that is most
pronouncedin the more symptomatic patient subgroups; how-
ever, this didnot translate into improved exercise tolerance
[29]. The multicenter, double-blind,placebo-controlled ran-
domized angiogenic gene therapy (AGENT) trial of direct
intracoronary administration of adenovirus encoding FGF-
4 demonstrated safety and showed a overall trend towards
improvement in exercise tolerance [30]. Concordant with the
FIRST trial, greatest improvement were noted in patients with
baseline ETT ≤10 min or in the sicker patients [30].
Other growth factors
Hepatocyte growth factor also has angiogenic activity via
induction of VEGF. Recombinant HGF was shown to
161
Fig. 2. Typical H + E example of phVEGF165-treated heart. New blood vessels are seen within angiomatous structure after intramyocardial injection of
phVEGF165. The cells are primarily composed of a few endothelial cells forming a ring. Reproduced from Schwarz et al. [71].
stimulate angiogenesis in rabbit ischemic limb model [31].
Angiopoietin-1 and angiopoietin-2 modify angiogenesis by
causing maturation and stability in the new vessels after
VEGF gene therapy [32]. An adenoviral vector was used
to achieve gene transfer of active form of hypoxia inducible
factor-1 alpha (HIF-1 alpha). HIF-1 alpha has been shown to
augment collateral vessels in animal models [33] and clinical
results are pending. Other factors like monocyte chemotactic
protein-1 and platelet-derived growth factor [34] may medi-
ate angiogenesis via VEGF.
In summary, the current weight of evidence favors direct
intramyocardial delivery of growth factors, but intracoronary
and intravenous delivery has not been consistently success-
full. In the future, enhanced local delivery of these growth
factors using ultrasound or other techniques may make pe-
ripheral intravenous injection feasible by significantly aug-
menting local delivery.
Combination of bypass surgery and gene therapy
Therapeutic angiogenesis may play an important role in
patients who are not candidates for any revascularization and
also in the group of patients who require CABG, but com-
plete revascularization may not be feasible in some arterial
distributions. These patients might benefit from a combined
approach of CABG and angiogenesis. Feasibility of this
combined approach has been shown in small preliminary
trials [21, 25, 28]. Such an approach may open more avenues
such as decreased utilization of saphenous vein grafts with
limited patency if indeed gene therapy appears to benefit
ungraftable territories.
Risks/concerns with growth–factor-mediated myocardial
angiogenesis
The main concern about growth–factor-mediated angiogene-
sis is pathological angiogenesis. This is thought to play a role
in several diseases including tumor growth, diabetic prolif-
erative retinopathy, and progression of atherosclerosis [35].
Growth factors may contribute to the growth of malignant tu-
mors, and because of this patients with a history of cancer has
been excluded from the trials. There has been no report of in-
creased new malignancy in the clinical trials to date. Another
concern is development/woresing of diabetic retinopathy. At
present there are no reports of neovascularization in the retina,
despite formal ophthalmological exams in most of the clinical
trials. Initially diabetics were excluded, but several trials now
include diabetics without retinopathy. In the clinical trials so
far there has been no increase in acute ischemic syndromes or
progression of atherosclerosis observed on serial angiogra-
phy. Despite initial concerns, treatment with both VEGF and
FGF has been well tolerated in the clinical trials. Both drugs
may cause transient hypotension at high doses or with rapid
infusion. Slowing the infusion rate may help in these patients.
There have been rare reports of proteinuria and thrombocy-
topenia with FGF, and spider angiomas and peripheral edema
with VEGF.
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Fig. 3. (A) Collateralization of stenoses (arrow): a diagonal branch occluded just distal to its origin is filled through the newly grown capillaries. At the site of
injection of the FGF-I, a capillary network couldbe seen sprouting out from the coronary artery into the myocardium. (B) The peripherally stenosed LAD is
filled through newly grown capillaries. Such “neocapillary vessels” can alsoprovide a collateral circulation around additional distal stenosesof the LAD and
bring about retrograde filling of ashort segment of the artery distal to the stenosis. Reproduced from Schumacher et al. [28].
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Coronary artery restenosis and angiogenesis
The incidence of post-PCI restenosis remains approximately
15–20% in native coronary arteries and significantly higher
in vein grafts [7]. Current solutions that are being investi-
gated include gene therapy for amelioration of restenosis.
Antisense constructs against c-myc, ras, bcl-x, etc. have de-
creased intimal thickening in experimental models [36, 37].
Smooth muscle cell proliferation can be reduced by blocking
PDGF [38]. To be successful, all the above molecules have
to be efficiently transfected into host genome. One efficient
method could be autologous in vitro transfection outside the
body and implantation at the needed site. VEGF stimulates
nitric oxide [39] and releases prostaglandin-I which prevent
smooth muscle cell proliferation. Local delivery of VEGF to
prevent re-stenosis may also be potentially useful. The cur-
rent availability of drug-coated stents with <5% restenosis
[40, 41] may however limit the usefulness and affect devel-
opment of these investigative modalities.
Role of myocardial angiogenesis in heart failure
A strategy of “molecular ventricular assistance” has been
proposed for treatment of refractory HF [42]. Prior studies
have revealed that reduced expression of sarcoplasmic retic-
ulum Ca2+-ATPase (SERCA) plays a role in congestive HF
[43]. Miyamoto et al. [44] showed that adenoviral overex-
pression of SERCA 2A restored systolic and diastolic func-
tion in a rat model and left ventricular size was reduced.
SERCA 2a expression decreased Ca2+ prevents activation of
calcineurin, thus preventing myocyte hypertrophy. Overex-
pression of SERCA rescues calcium cycling in the failing
heart [45].
Table 3. Pre-clinical and clinical studies of cell transplantation (adapted from [70])
Author Animal model Transplantation type Cell type Time after infarct LV∗ function
Marelli et al. [57] Dog Differentiated Skeletal myoblasts Immediate N/A
Murry et al. [51] Rat Differentiated Skeletal myoblasts Immediate N/A
Taylor et al. [59] Rabbit Differentiated Skeletal myoblasts Immediate Improved
Li et al. [55] Rat Differentiated Smooth muscle cell 4 weeks Improved
Li et al. [56] Porcine Differentiated Heart cells 4 weeks N/A
Rajnoch et al. [58] Sheep Differentiated Skeletal myoblasts 3 weeks Improved
Tomita et al. [61] Rat Stem cell–direct Bone marrow 3 weeks Improved
Kocher et al. [60] Rat Stem cell–direct Bone marrow 48 h Improved
Beltrami et al. [63] Human Stem cell mobilization Cardiac myoblasts 4–12 days Increased muscle mass
Jackson et al. [62] Mouse Stem cell mobilization Myocytes, endothelial cells 4 weeks Endothelial engraftment
Askari et al. [66] Rat Stem cell mobilization + Skeletal myoblasts 4 weeks Increase in left ventricular mass
direct transplantation and better cardiac function
∗LV: left ventricular function; N/A: not available.
Beta adrenergic receptors (beta-ARs) play a major role
in HF. Down-regulated beta-ARs, can be remedied with in-
tracoronary injection of viral particles encoding beta-AR in
rabbits with persistent expression for up to 3 weeks [46]. To
circumvent beta receptors, adenoviral gene transfer of vaso-
pressin V2 receptors which increase dp/dt has been performed
in rats [47]. Intracoronary injection of adenoviral beta-ARK1
inhibitor lead to improved systolic function in rabbit mod-
els with increased dP/dt. A potential problem with this is
sustained adrenergic stimulation and arrhythmias. Apopto-
sis, programmed cell death, seems to play an important role
in HF and in vitro studies in animal models using aden-
oviral Bcl-2 to block apoptosis mediated by p53 have been
performed.
Cell transplantation
The potential of cell therapy in cardiovascular diseases is
rapidly evolving. Two types of cells may be used for this
therapy. These are differentiated cells and stem cells. This ex-
citing new approach for the treatment of HF and myocardial
ischemia [48] can also be used as compliment to gene therapy.
Fetal cardiomyocytes [49], autologous skeletal myoblasts
[50–52] and mesenchymal stem cells have shown to improve
myocardial function in pre-clinical trials. Initial studies eval-
uated autologous cell transplantation using cardiac myocytes
or skeletal muscle cells into normal hearts [53, 54]. The im-
portant observation from these experiments was that ventric-
ular arrhythmias were not induced by cell engraftment.
Subsequently, studies were done looking at injured my-
ocardium in animal models [55–59]. Myocardial injury was
induced by ligating artery or by cryoinjury to theepicardium.
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Transplantation of differentiated cells was demonstrated to
be successful in several animal models (Table 3). In these
studies, fetal myoblasts did not offer improved efficacy
when compared to other cells. The mechanism by how these
cells help is not yet well understood. Whether it improves
contractility of infarcted area or helps with post-infarct
remodeling [51] is yet to be delineated but more likely it
affects remodeling. If cell transplantation indeed improves
contractility, then time to transplantation should not play a
major role in efficacy. But, if post-infarct remodeling is the
major mechanism, then time to cell transplantation becomes
critical. Regeneration of infarcted myocardium using stem
Fig. 4. Treatment algorithm for patients with refractory myocardial ischemia.
cells can be done either by direct injection into myocardium
[60, 61] or by mobilizing specific cell population [62, 63] by
various stimulating mediators like VEGF [64]. The combina-
tion of replacing senescent cells by cell transplantation and
deliver gene products via gene therapy (VEGF) has led to
enhanced capillary density and blood flow in rat hearts [65].
Askari et al., studied the effects of stem-cell mobilization
by use of granulocyte colony-stimulating factor with or
without transplantation of syngeneic skeletal myoblasts
cells and demonstrated that a combined strategy of gene
transfer and stem-cell mobilization, results in regeneration
of myocardium in a model of ischemic cardiomyopathy [66].
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This combined modality has a potential to offer a new
treatment modality for ischemia and HF. Several studies of
stem cell transplantation are summarized in Table 3.
After initial success in animal studies, clinical trials have
been initiated. Hamano et al., reported their experience with
mononuclear rich autologous cell injection into myocardium
along with CABG [67] and demonstrated improved local wall
thickening dynamics, presumably due to the angiogenesis in-
duced by the treatment. In patients afflicted with end stage
HF, pleuripotent adult stem cell transplantation has lead to
some evidence of myocardial regeneration [60–62]. HMG
CoA reductase inhibitors which have been shown to be sig-
nificantly beneficial in patients with CAD have been shown to
increase the circulating levels of endothelial progenitor cells
[68]. There seems to be significant potential for autologous
cell transplantation to heal injured myocardium [69, 70] but
needs to be validated in prospective trials.
Conclusions
A significant proportion of patients with symptomatic CAD
and end stage HF may not be candidates for conventional ther-
apeutic options like PCI or CABG and heart transplantation.
Therapeutic angiogenesis with growth factors, cell transplan-
tation with myoblasts and genetically engineered cells may
improve morbidity in these cohort of patients. Current trials
have only enrolled patients with severe symptomatic CAD or
peripheral vascular disease. In the future, it may also benefit
patients with ischemic cardiomyopathy, end-stage HF, post
cardiac transplant atherosclerosis, severe restenosis, inher-
ited lipid disorders and patients with microvascular disease.
Cell transplantation with differentiated and stem cells have
shown significant potential in animal studies and preliminary
reports of small case series but needs to be prospectively val-
idated in larger appropriately designed studies. The future
may hold many more therapeutic options for patients with
advanced ischemic heart disease. Figure 4 is a simplified al-
gorithm for the approach and management of patients with
refractory myocardial ischemia not amenable to traditional
methods of revascularization.
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